

# **An Introduction to Pharmaceutical Sciences**

Production, Chemistry, Techniques  
and Technology

Jiben Roy



**Biohealthcare**  
PUBLISHING (OXFORD) LIMITED  
Oxford · New York

# Contents

|                                                                 |               |
|-----------------------------------------------------------------|---------------|
| <i>Preface</i>                                                  | <i>xv</i>     |
| <i>Acknowledgements</i>                                         | <i>xvii</i>   |
| <i>List of figures and tables</i>                               | <i>xix</i>    |
| <i>Abbreviations</i>                                            | <i>xxxvii</i> |
| <i>About the author</i>                                         | <i>xli</i>    |
| <b>1 Introduction</b>                                           | <b>1</b>      |
| 1.1 The theme of the book                                       | 3             |
| 1.2 Development of the pharmaceutical industry and its impact   | 5             |
| 1.3 Important milestones in the introduction of pharmaceuticals | 15            |
| 1.4 The multidisciplinary nature of pharmaceutical sciences     | 16            |
| 1.5 Medicinal trees                                             | 17            |
| 1.6 Pharmaceutical research and development                     | 18            |
| 1.7 Pharmaceutical technology                                   | 20            |
| 1.8 Pharmaceutical economics                                    | 21            |
| 1.9 The world pharmaceutical market                             | 22            |
| 1.10 Embedded ethics in the pharmaceutical industry             | 25            |
| <b>2 Career prospects in the pharmaceutical industry</b>        | <b>29</b>     |
| 2.1 Job opportunities in the pharmaceutical industry            | 30            |
| 2.2 Education and training                                      | 35            |
| 2.3 Various departments of a pharmaceutical company             | 37            |
| 2.4 Mergers and acquisitions in the pharmaceutical industry     | 39            |
| 2.5 Careers for pharmaceutical physicians                       | 41            |
| <b>3 Drugs, medicines, and regulatory authorities</b>           | <b>43</b>     |
| 3.1 Drugs and medicines: brand names and generic names          | 45            |
| 3.2 Drug names                                                  | 47            |

|          |                                                                                 |            |
|----------|---------------------------------------------------------------------------------|------------|
| 3.3      | Drug discovery and the drug development process                                 | 49         |
| 3.4      | Marketing of generic drugs in the USA or Europe                                 | 52         |
| 3.5      | The role of pharmacopoeias                                                      | 61         |
| 3.6      | Regulatory agencies                                                             | 62         |
| <b>4</b> | <b>Bulk drugs or active pharmaceutical ingredients</b>                          | <b>69</b>  |
| 4.1      | Bulk drugs and bulk drug plants                                                 | 71         |
| 4.2      | Lab to manufacturing level scale-up                                             | 72         |
| 4.3      | Bulk drug manufacturing                                                         | 74         |
| 4.4      | Solubility of API                                                               | 78         |
| 4.5      | Stereoisomeric bulk drugs                                                       | 82         |
| 4.6      | Stability, degradation, and impurity profiles of bulk drugs                     | 91         |
| 4.7      | Drug development, scale up, and analytical development                          | 101        |
| 4.8      | Green chemistry in bulk drug manufacturing                                      | 104        |
| <b>5</b> | <b>Formulated drugs 1</b>                                                       | <b>111</b> |
| 5.1      | Introduction                                                                    | 114        |
| 5.2      | The role of excipients                                                          | 115        |
| 5.3      | The classification of dosage forms                                              | 124        |
| 5.4      | Formulation and manufacturing of tablets                                        | 126        |
| 5.5      | Problems with tablet manufacturing and the use of process analytical technology | 128        |
| 5.6      | Liquid dosage forms                                                             | 133        |
| 5.7      | Production of oral solution and suspension dosage forms                         | 135        |
| 5.8      | Dosage forms in pediatrics                                                      | 137        |
| <b>6</b> | <b>Formulated drugs 2</b>                                                       | <b>141</b> |
| 6.1      | Dosage forms according to route of administration                               | 143        |
| 6.2      | The parenteral route of administration                                          | 143        |
| 6.3      | The pulmonary route of administration                                           | 148        |
| <b>7</b> | <b>The stability of medicines</b>                                               | <b>153</b> |
| 7.1      | Stability – an essential criterion of medicines                                 | 155        |
| 7.2      | Label instructions and stability of medicines at home                           | 164        |
| 7.3      | Drug stability kinetics                                                         | 165        |
| 7.4      | Stabilization of pharmaceutical products                                        | 169        |
| 7.5      | The International Conference on Harmonization                                   | 172        |

---

|           |                                                                   |            |
|-----------|-------------------------------------------------------------------|------------|
| 7.6       | Product stability protocol                                        | 173        |
| 7.7       | Packaging and stability of medicines                              | 178        |
| <b>8</b>  | <b>Quality assurance in medicines</b>                             | <b>183</b> |
| 8.1       | The concept of quality assurance                                  | 185        |
| 8.2       | Evolution of quality testing and safety of medicine               | 186        |
| 8.3       | Quality management systems                                        | 189        |
| 8.4       | Good manufacturing practice in sterile production                 | 191        |
| 8.5       | Validation                                                        | 196        |
| 8.6       | Contamination control in formulation factory                      | 197        |
| 8.7       | Limits of good quality                                            | 201        |
| <b>9</b>  | <b>Pharmacological concepts and drugs</b>                         | <b>205</b> |
| 9.1       | Drug action                                                       | 207        |
| 9.2       | Routes of drug administration                                     | 208        |
| 9.3       | Mechanism of oral medication                                      | 210        |
| 9.4       | Drug absorption, bioavailability, and activity                    | 216        |
| 9.5       | Pharmacokinetic profile of oral and IV dosage forms               | 219        |
| 9.6       | Metabolism, or biotransformation of drugs                         | 220        |
| 9.7       | Bioavailability, bioequivalence, and generic drugs                | 221        |
| 9.8       | Safety and the toxic effects of drugs                             | 224        |
| 9.9       | The ideal pharmacokinetics and pharmacodynamics of a drug         | 226        |
| <b>10</b> | <b>The top five most common or long-selling drugs</b>             | <b>231</b> |
| 10.1      | Amoxicillin – the largest-selling $\beta$ -lactam antibiotic      | 232        |
| 10.2      | Aspirin – the longest-selling drug on the market                  | 252        |
| 10.3      | Paracetamol – the best-selling antipyretic analgesic in the world | 267        |
| 10.4      | Ranitidine – the world's leading prescribed drug                  | 280        |
| 10.5      | Ciprofloxacin – the best-selling antibacterial in the world       | 288        |
| <b>11</b> | <b>Life-style drugs, statins, and COX-2 drugs</b>                 | <b>297</b> |
| 11.1      | An introduction to sildenafil citrate (Viagra)                    | 298        |
| 11.2      | Discovery of sildenafil citrate                                   | 299        |
| 11.3      | Synthesis of sildenafil citrate                                   | 303        |
| 11.4      | How does sildenafil work in the body?                             | 305        |
| 11.5      | Dosage form of sildenafil citrate                                 | 307        |

|           |                                                                 |            |
|-----------|-----------------------------------------------------------------|------------|
| 11.6      | Atorvastatin – a brief introduction                             | 308        |
| 11.7      | Discovery of atorvastatin (Lipitor)                             | 309        |
| 11.8      | Synthesis of atorvastatin calcium                               | 311        |
| 11.9      | Stereochemistry and atorvastatin                                | 312        |
| 11.10     | Mechanism of action of atorvastatin                             | 315        |
| 11.11     | Dosage forms of atorvastatin                                    | 317        |
| 11.12     | Celecoxib and rofecoxib                                         | 318        |
| 11.13     | The mechanism of COX-2 inhibition by celecoxib and rofecoxib    | 319        |
| 11.14     | Metabolism and cardiotoxicity of celecoxib and rofecoxib        | 322        |
| <b>12</b> | <b>Counterfeit drugs and drug abuse</b>                         | <b>327</b> |
| 12.1      | Counterfeit drugs                                               | 328        |
| 12.2      | Anticounterfeiting strategies                                   | 330        |
| 12.3      | Risks of internet pharmacies                                    | 334        |
| 12.4      | Drug abuse                                                      | 335        |
| <b>13</b> | <b>New pharmaceutical technology and pharmaceuticals</b>        | <b>349</b> |
| 13.1      | Biologics                                                       | 350        |
| 13.2      | Nanomedicines by nanotechnology                                 | 352        |
| 13.3      | Regenerative medicines                                          | 354        |
| 13.4      | Transdermal patch technology                                    | 355        |
| <b>14</b> | <b>Future prospects for the pharmaceutical industry</b>         | <b>357</b> |
| 14.1      | Introduction                                                    | 360        |
| 14.2      | Carbon and silicon                                              | 360        |
| 14.3      | The role of the pharmaceutical industry in increasing longevity | 361        |
| 14.4      | Aspirin to Avastin                                              | 363        |
| 14.5      | Monoclonal antibody drugs                                       | 364        |
| 14.6      | The future shape of the pharmaceutical industry                 | 366        |
| 14.7      | Personalized medicine                                           | 367        |
| 14.8      | Treatment of the increasing ageing population                   | 369        |
| 14.9      | Controlled-release drugs using a magnetic field switch          | 371        |
| 14.10     | The world pharmaceutical market and employment                  | 371        |
| 14.11     | Stronger generics markets in future                             | 373        |
| 14.12     | Generic biologics and biosimilars market potential              | 374        |
| 14.13     | Emerging new markets                                            | 376        |
| 14.14     | Biotechnology – a way forward                                   | 377        |
| 14.15     | Stem cell therapy – hope for the future                         | 378        |

---

|                                                                                          |            |
|------------------------------------------------------------------------------------------|------------|
| 14.16 Technology and automation                                                          | 380        |
| 14.17 The future pharmaceutical R&D work force                                           | 381        |
| <b>15 Pharmaceutical case studies</b>                                                    | <b>385</b> |
| 15.1 Medicines given to an 11-year-old girl following<br>adenoidectomy and tonsillectomy | 386        |
| 15.2 Drug–food interactions                                                              | 387        |
| 15.3 Effervescent tablets                                                                | 389        |
| <b>Index</b>                                                                             | <b>391</b> |